Detalhe da pesquisa
1.
Discovery of potent, selective and orally bioavailable imidazo[1,5-a]pyrazine derived ACK1 inhibitors.
Bioorg Med Chem Lett
; 23(4): 979-84, 2013 Feb 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-23317569
2.
Combined CDK4/6 and ERK1/2 Inhibition Enhances Antitumor Activity in NF1-Associated Plexiform Neurofibroma.
Clin Cancer Res
; 29(17): 3438-3456, 2023 09 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-37406085
3.
Aminopurine based JNK inhibitors for the prevention of ischemia reperfusion injury.
Bioorg Med Chem Lett
; 22(3): 1427-32, 2012 Feb 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-22226655
4.
AC220 is a uniquely potent and selective inhibitor of FLT3 for the treatment of acute myeloid leukemia (AML).
Blood
; 114(14): 2984-92, 2009 Oct 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-19654408
5.
Novel series of pyrrolotriazine analogs as highly potent pan-Aurora kinase inhibitors.
Bioorg Med Chem Lett
; 21(18): 5296-300, 2011 Sep 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-21802948
6.
Imidazo[1,5-a]pyrazines: orally efficacious inhibitors of mTORC1 and mTORC2.
Bioorg Med Chem Lett
; 21(7): 2092-7, 2011 Apr 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-21353551
7.
4-Quinazolinyloxy-diaryl ureas as novel BRAFV600E inhibitors.
Bioorg Med Chem Lett
; 21(18): 5342-6, 2011 Sep 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-21807507
8.
Substrate reduction therapy for Krabbe disease and metachromatic leukodystrophy using a novel ceramide galactosyltransferase inhibitor.
Sci Rep
; 11(1): 14486, 2021 07 14.
Artigo
em Inglês
| MEDLINE | ID: mdl-34262084
9.
ERK Inhibitor LY3214996-Based Treatment Strategies for RAS-Driven Lung Cancer.
Mol Cancer Ther
; 20(4): 641-654, 2021 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-33536188
10.
Correction: Evaluation of ERK as a therapeutic target in acute myelogenous leukemia.
Leukemia
; 34(9): 2543, 2020 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-32144400
11.
Molecular dissection of CRC primary tumors and their matched liver metastases reveals critical role of immune microenvironment, EMT and angiogenesis in cancer metastasis.
Sci Rep
; 10(1): 10725, 2020 07 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-32612211
12.
Low-Dose Vertical Inhibition of the RAF-MEK-ERK Cascade Causes Apoptotic Death of KRAS Mutant Cancers.
Cell Rep
; 31(11): 107764, 2020 06 16.
Artigo
em Inglês
| MEDLINE | ID: mdl-32553168
13.
ERK Inhibitor LY3214996 Targets ERK Pathway-Driven Cancers: A Therapeutic Approach Toward Precision Medicine.
Mol Cancer Ther
; 19(2): 325-336, 2020 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-31744895
14.
Arylcarboxyamino-substituted diaryl ureas as potent and selective FLT3 inhibitors.
Bioorg Med Chem Lett
; 19(17): 5182-5, 2009 Sep 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-19646870
15.
Correction: Combined CDK4/6 and ERK1/2 Inhibition Enhances Antitumor Activity in NF1-Associated Plexiform Neurofibroma.
Clin Cancer Res
; 30(9): 1992, 2024 May 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-38690594
16.
Aurora A-Selective Inhibitor LY3295668 Leads to Dominant Mitotic Arrest, Apoptosis in Cancer Cells, and Shows Potent Preclinical Antitumor Efficacy.
Mol Cancer Ther
; 18(12): 2207-2219, 2019 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-31530649
17.
Crystal structures of human adenosine kinase inhibitor complexes reveal two distinct binding modes.
J Med Chem
; 49(23): 6726-31, 2006 Nov 16.
Artigo
em Inglês
| MEDLINE | ID: mdl-17154503
18.
Effects of SP500263, a novel, potent antiestrogen, on breast cancer cells and in xenograft models.
Cancer Res
; 62(5): 1439-42, 2002 Mar 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-11888917
19.
Evaluation of ERK as a therapeutic target in acute myelogenous leukemia.
Leukemia
; 34(2): 625-629, 2020 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-31455850
20.
Design, synthesis, and structure-activity relationship of 6-alkynylpyrimidines as potent adenosine kinase inhibitors.
J Med Chem
; 45(17): 3639-48, 2002 Aug 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-12166937